Ceftriaxone Treatment for Neuronal Deficits: A Histological and MEMRI Study in a Rat Model of Dementia with Lewy Bodies.
Ying-Jui HoJun-Cheng WengChih-Li LinMei-Shiuan ShenHsin-Hua LiWen-Chieh LiaoNu-Man TsaiChing-Sui HungTe-Jen LaiI-Yen LeePublished in: Behavioural neurology (2018)
Dementia with Lewy bodies (DLB) is characterized by neuronal deficits and α-synuclein inclusions in the brain. Ceftriaxone (CEF), a β-lactam antibiotic, has been suggested as a therapeutic agent in several neurodegenerative disorders for its abilities to counteract glutamate-mediated toxicity and to block α-synuclein polymerization. By using manganese-enhanced magnetic resonance imaging (MEMRI) and immunohistochemistry, we measured the effects of CEF on neuronal activity and α-synuclein accumulation in the brain in a DLB rat model. The data showed that CEF corrected neuronal density and activity in the hippocampal CA1 area, suppressed hyperactivity in the subthalamic nucleus, and reduced α-synuclein accumulation, indicating that CEF is a potential agent in the treatment of DLB.
Keyphrases
- cerebral ischemia
- magnetic resonance imaging
- parkinson disease
- mild cognitive impairment
- traumatic brain injury
- subarachnoid hemorrhage
- cognitive impairment
- brain injury
- oxidative stress
- blood brain barrier
- magnetic resonance
- machine learning
- electronic health record
- risk assessment
- big data
- artificial intelligence
- replacement therapy